<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732225</url>
  </required_header>
  <id_info>
    <org_study_id>M07-015</org_study_id>
    <nct_id>NCT00732225</nct_id>
  </id_info>
  <brief_title>DisCoVisc Comparative Evaluation</brief_title>
  <official_title>A Prospective, Non-randomized Comparison of DisCoVisc to Dispersive and Cohesive Ophthalmic Viscosurgical Devices (OVDs) in Non-eventful Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the ability of DisCoVisc to that of other Opthalmic Viscosurgical Devices
      (OVDs) (DuoVisc®, BioVisc®, Healon5®, or Amvisc PLUS) regarding endothelial protection and
      anterior chamber space maintenance during non-eventful cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Loss of Endothelial Cells</measure>
    <time_frame>2 months following surgery</time_frame>
    <description>Percentage of corneal endothelial cells lost 2 months after surgery as compared to the number of corneal endothelial cells measured before the operation. Corneal Endothelial Cells are measured by counting the number of cells on an image taken by specular microscope.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Corneal Edema</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings:
0 - None
- Mild, slight localized or generalized edema
- Moderate, significant localized or generalized edema
- Severe, advanced localized or generalized edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Aqueous Flare</measure>
    <time_frame>1 day following surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings:
0-None: No visible flare when compared with the normal eye.
Mild: Flare visible against dark papillary background but not visible against iris background.
Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as the dark papillary background.
Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous Signs - Aqueous Cells</measure>
    <time_frame>1 day following surgery</time_frame>
    <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings:
0 - None
- 1 to 5 cells
- 6 to 15 cells
- 16 to 30 cells
- &gt;30 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>1 day following surgery</time_frame>
    <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure between 10 mmHg and 20 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</measure>
    <time_frame>Time of Surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye During Anterior Capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Survey - Anterior Chamber Dome Maintenance During Phacoemulsification</measure>
    <time_frame>Time of Surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye during Phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Survey - Anterior Chamber Dome Maintenance During IOL Insertion</measure>
    <time_frame>Time of Surgery</time_frame>
    <description>Surgeon reporting of Anterior Chamber Dome Maintenance During Intraocular Lens (IOL) insertion into a patient's eye. Evaluated on a subjective scale and reported as percent by response. The scale, from worst to best, is as follows: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>DisCoVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DuoVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healon5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amvisc Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bausch &amp; Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DisCoVisc</intervention_name>
    <description>DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.</description>
    <arm_group_label>DisCoVisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DuoVisc</intervention_name>
    <description>DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.</description>
    <arm_group_label>DuoVisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioVisc</intervention_name>
    <description>BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.</description>
    <arm_group_label>BioVisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Healon5</intervention_name>
    <description>Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.</description>
    <arm_group_label>Healon5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amvisc Plus</intervention_name>
    <description>Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.</description>
    <arm_group_label>Amvisc Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral operable cataracts

        Exclusion Criteria:

          -  Preoperative Endothelial Cell Count (ECC) ≤1500 cells/mm2

          -  Intraocular Pressure (IOP) &gt; 21

          -  History of ocular inflammation

          -  Systemic or ocular diseases affecting corneal endothelium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>49 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>March 31, 2010</results_first_submitted>
  <results_first_submitted_qc>June 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>June 30, 2010</last_update_submitted>
  <last_update_submitted_qc>June 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rick Potvin/Director - Global Scientific Market Affairs</name_title>
    <organization>Alcon Research</organization>
  </responsible_party>
  <keyword>DisCoVisc OVD</keyword>
  <keyword>Ophthalmic Viscosurgical Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Preoperatively, subjects were examined to ensure they met the inclusion/exclusion criteria. Patients were &gt;49 years of age, of any race and either gender. Patients had operable cataracts in at least one eye and were able to provide informed consent</recruitment_details>
      <pre_assignment_details>As access to Ophthalmic Viscosurgical Devices (OVDs) was limited, patients received whichever OVD was in stock at the time of surgery. 51 patients had a different OVD used in each eye. As a result, their demographic data is included in 2 OVD groups, resulting in a total of 224 patients (when group totals are added).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DisCoVisc</title>
          <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
        </group>
        <group group_id="P2">
          <title>DuoVisc</title>
          <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
        </group>
        <group group_id="P3">
          <title>BioVisc</title>
          <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
        </group>
        <group group_id="P4">
          <title>Healon5</title>
          <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
        </group>
        <group group_id="P5">
          <title>AmviscPlus</title>
          <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71">76 eyes of 71 patients</participants>
                <participants group_id="P2" count="40">41 eyes of 40 patients</participants>
                <participants group_id="P3" count="26">26 eyes of 26 patients</participants>
                <participants group_id="P4" count="33">33 eyes of 33 patients</participants>
                <participants group_id="P5" count="54">55 eyes of 54 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60">64 eyes of 60 patients</participants>
                <participants group_id="P2" count="32">33 eyes of 32 patients</participants>
                <participants group_id="P3" count="23">23 eyes of 23 patients</participants>
                <participants group_id="P4" count="29">29 eyes of 29 patients</participants>
                <participants group_id="P5" count="48">48 eyes of 48 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DisCoVisc</title>
          <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
        </group>
        <group group_id="B2">
          <title>DuoVisc</title>
          <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
        </group>
        <group group_id="B3">
          <title>BioVisc</title>
          <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
        </group>
        <group group_id="B4">
          <title>Healon5</title>
          <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
        </group>
        <group group_id="B5">
          <title>AmviscPlus</title>
          <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="54"/>
            <count group_id="B6" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age not available for the following: 7 Discovisc patients, 11 Duovisc patients, 3 Biovisc patients, 4 Amvisc Plus patients. Total mean age and standard deviation not calculated.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="9.54"/>
                    <measurement group_id="B2" value="67.31" spread="12.61"/>
                    <measurement group_id="B3" value="71.48" spread="8.56"/>
                    <measurement group_id="B4" value="67.03" spread="12.13"/>
                    <measurement group_id="B5" value="66.24" spread="10.51"/>
                    <measurement group_id="B6" value="67.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender not available for the following: 2 Discovisc patients, 2 Duovisc patients, 1 Biovisc patient, 2 Amvisc Plus patients.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Loss of Endothelial Cells</title>
        <description>Percentage of corneal endothelial cells lost 2 months after surgery as compared to the number of corneal endothelial cells measured before the operation. Corneal Endothelial Cells are measured by counting the number of cells on an image taken by specular microscope.</description>
        <time_frame>2 months following surgery</time_frame>
        <population>This data was collected on the eyes of patients attending the visit 2 months after surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Loss of Endothelial Cells</title>
          <description>Percentage of corneal endothelial cells lost 2 months after surgery as compared to the number of corneal endothelial cells measured before the operation. Corneal Endothelial Cells are measured by counting the number of cells on an image taken by specular microscope.</description>
          <population>This data was collected on the eyes of patients attending the visit 2 months after surgery.</population>
          <units>Percent Loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="20.72"/>
                    <measurement group_id="O2" value="15.66" spread="11.03"/>
                    <measurement group_id="O3" value="23.69" spread="13.47"/>
                    <measurement group_id="O4" value="25.70" spread="13.94"/>
                    <measurement group_id="O5" value="23.04" spread="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs - Corneal Edema</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings:
0 - None
- Mild, slight localized or generalized edema
- Moderate, significant localized or generalized edema
- Severe, advanced localized or generalized edema</description>
        <time_frame>1 day after surgery</time_frame>
        <population>This data was collected on all eyes of patients attending the 1-day visit.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs - Corneal Edema</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have corneal edema at each of the following gradings:
0 - None
- Mild, slight localized or generalized edema
- Moderate, significant localized or generalized edema
- Severe, advanced localized or generalized edema</description>
          <population>This data was collected on all eyes of patients attending the 1-day visit.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.33"/>
                    <measurement group_id="O2" value="78.05"/>
                    <measurement group_id="O3" value="37.50"/>
                    <measurement group_id="O4" value="63.64"/>
                    <measurement group_id="O5" value="54.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67"/>
                    <measurement group_id="O2" value="19.51"/>
                    <measurement group_id="O3" value="37.50"/>
                    <measurement group_id="O4" value="30.30"/>
                    <measurement group_id="O5" value="32.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00"/>
                    <measurement group_id="O2" value="2.44"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="6.06"/>
                    <measurement group_id="O5" value="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs – Aqueous Flare</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings:
0-None: No visible flare when compared with the normal eye.
Mild: Flare visible against dark papillary background but not visible against iris background.
Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as the dark papillary background.
Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
        <time_frame>1 day following surgery</time_frame>
        <population>This data was collected on all eyes of patients attending the 1 day postoperative visit.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs – Aqueous Flare</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Flare at each of the following gradings:
0-None: No visible flare when compared with the normal eye.
Mild: Flare visible against dark papillary background but not visible against iris background.
Moderate: Flare is visible with the slit-lamp beam aimed onto the iris surface as well as the dark papillary background.
Severe: Very dense flare. May also present as a hazy appearance of anterior segment structures when viewed with low power magnification of the slit-lamp.</description>
          <population>This data was collected on all eyes of patients attending the 1 day postoperative visit.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.00"/>
                    <measurement group_id="O2" value="75.61"/>
                    <measurement group_id="O3" value="41.67"/>
                    <measurement group_id="O4" value="63.64"/>
                    <measurement group_id="O5" value="54.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33"/>
                    <measurement group_id="O2" value="19.51"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="24.24"/>
                    <measurement group_id="O5" value="34.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67"/>
                    <measurement group_id="O2" value="4.88"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="12.12"/>
                    <measurement group_id="O5" value="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aqueous Signs - Aqueous Cells</title>
        <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings:
0 - None
- 1 to 5 cells
- 6 to 15 cells
- 16 to 30 cells
- &gt;30 cells</description>
        <time_frame>1 day following surgery</time_frame>
        <population>This data was collected on all eyes of patients attending the 1 day post-operative visit.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous Signs - Aqueous Cells</title>
          <description>Measured as the percentage of patient's eyes subjectively evaluated to have Aqueous Cells at each of the following gradings:
0 - None
- 1 to 5 cells
- 6 to 15 cells
- 16 to 30 cells
- &gt;30 cells</description>
          <population>This data was collected on all eyes of patients attending the 1 day post-operative visit.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.00"/>
                    <measurement group_id="O2" value="80.49"/>
                    <measurement group_id="O3" value="45.83"/>
                    <measurement group_id="O4" value="63.64"/>
                    <measurement group_id="O5" value="56.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00"/>
                    <measurement group_id="O2" value="17.07"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="27.27"/>
                    <measurement group_id="O5" value="36.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="2.44"/>
                    <measurement group_id="O3" value="29.17"/>
                    <measurement group_id="O4" value="9.09"/>
                    <measurement group_id="O5" value="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure between 10 mmHg and 20 mmHg.</description>
        <time_frame>1 day following surgery</time_frame>
        <population>This data was collected on all eyes of patients attending the 1 day postoperative visit with the exception of the following: 3 DisCoVisc patients, 4 DuoVisc patients, 1 Healon5 patient, and 4 Amvisc Plus patients.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>Measure of intraocular pressure of a patient's eye via tonometry one day after surgery. Measured in mmHg. Normal intraocular pressure between 10 mmHg and 20 mmHg.</description>
          <population>This data was collected on all eyes of patients attending the 1 day postoperative visit with the exception of the following: 3 DisCoVisc patients, 4 DuoVisc patients, 1 Healon5 patient, and 4 Amvisc Plus patients.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.67" spread="3.88"/>
                    <measurement group_id="O2" value="17.78" spread="3.81"/>
                    <measurement group_id="O3" value="20.32" spread="7.39"/>
                    <measurement group_id="O4" value="19.88" spread="8.90"/>
                    <measurement group_id="O5" value="16.96" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye During Anterior Capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
        <time_frame>Time of Surgery</time_frame>
        <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 2 DisCoVisc eyes and 2 Healon5 eyes</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Survey - Anterior Chamber Dome Maintenance During Anterior Capsulotomy</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye During Anterior Capsulotomy. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance.</description>
          <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 2 DisCoVisc eyes and 2 Healon5 eyes</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="100.00"/>
                    <measurement group_id="O4" value="9.09"/>
                    <measurement group_id="O5" value="85.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Space Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.78"/>
                    <measurement group_id="O2" value="100.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="90.91"/>
                    <measurement group_id="O5" value="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Survey - Anterior Chamber Dome Maintenance During Phacoemulsification</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye during Phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
        <time_frame>Time of Surgery</time_frame>
        <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 17 DisCoVisc eyes, 19 DuoVisc eyes, 6 BioVisc eyes,3 Healon5 eyes, and 11 Amvisc Plus eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Survey - Anterior Chamber Dome Maintenance During Phacoemulsification</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance of a patient's eye during Phacoemulsification. Evaluated on a subjective scale and reported as percent by response. The following scale is used, from worst to best: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
          <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 17 DisCoVisc eyes, 19 DuoVisc eyes, 6 BioVisc eyes,3 Healon5 eyes, and 11 Amvisc Plus eyes.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Space Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.17"/>
                    <measurement group_id="O2" value="9.09"/>
                    <measurement group_id="O3" value="70.00"/>
                    <measurement group_id="O4" value="36.67"/>
                    <measurement group_id="O5" value="80.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.83"/>
                    <measurement group_id="O2" value="90.91"/>
                    <measurement group_id="O3" value="5.00"/>
                    <measurement group_id="O4" value="63.33"/>
                    <measurement group_id="O5" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Survey - Anterior Chamber Dome Maintenance During IOL Insertion</title>
        <description>Surgeon reporting of Anterior Chamber Dome Maintenance During Intraocular Lens (IOL) insertion into a patient's eye. Evaluated on a subjective scale and reported as percent by response. The scale, from worst to best, is as follows: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
        <time_frame>Time of Surgery</time_frame>
        <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 17 DisCoVisc eyes, 20 DuoVisc eyes, 6 BioVisc eyes,4 Healon5 eyes, and 14 Amvisc Plus eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>DisCoVisc</title>
            <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
          </group>
          <group group_id="O2">
            <title>DuoVisc</title>
            <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
          </group>
          <group group_id="O3">
            <title>BioVisc</title>
            <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
          </group>
          <group group_id="O4">
            <title>Healon5</title>
            <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
          </group>
          <group group_id="O5">
            <title>AmviscPlus</title>
            <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Survey - Anterior Chamber Dome Maintenance During IOL Insertion</title>
          <description>Surgeon reporting of Anterior Chamber Dome Maintenance During Intraocular Lens (IOL) insertion into a patient's eye. Evaluated on a subjective scale and reported as percent by response. The scale, from worst to best, is as follows: Flat, Shallow, Working Space Adequate, Full Chamber Maintenance</description>
          <population>This data was collected on all eyes of patients undergoing surgery with the exception of the following: 17 DisCoVisc eyes, 20 DuoVisc eyes, 6 BioVisc eyes,4 Healon5 eyes, and 14 Amvisc Plus eyes.</population>
          <units>Percentage of Eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shallow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="10.00"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working Chamber Adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39"/>
                    <measurement group_id="O2" value="9.52"/>
                    <measurement group_id="O3" value="90.00"/>
                    <measurement group_id="O4" value="24.14"/>
                    <measurement group_id="O5" value="68.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full Chamber Maintenance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.61"/>
                    <measurement group_id="O2" value="90.48"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="75.86"/>
                    <measurement group_id="O5" value="26.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events collected against the total number of eyes that could be affected instead of patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>DisCoVisc</title>
          <description>Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)</description>
        </group>
        <group group_id="E2">
          <title>DuoVisc</title>
          <description>Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)</description>
        </group>
        <group group_id="E3">
          <title>BioVisc</title>
          <description>Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)</description>
        </group>
        <group group_id="E4">
          <title>Healon5</title>
          <description>AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)</description>
        </group>
        <group group_id="E5">
          <title>AmviscPlus</title>
          <description>Bausch &amp; Lomb AmviscPlus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>At the time of surgery, patients were assigned to a study group based on the availability of study Ophthalmic Viscosurgical Devices (OVDs).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

